A drug originated from the curry spice turmeric could be used to treat stroke patients. The compound found in turmeric is a tack constituent in curry and has been found to help in protecting and regenerating brain cells after a stroke. According to The Stroke Association, it was the first momentous study, suggesting that the compound could serve stroke patients.
For centuries, turmeric has been used as part of conventional Indian Ayurvedic medicine and various lab studies have recommended one of its constituents, curcumin might have several health characteristics. It has anti-inflammatory properties and functions as an antioxidant. The US research team tailored curcumin to arise with new edition, CNG-001 that could pass the blood brain blockade.
They found it could repair damage at a molecular level and is associated with the survival of the brain cells’ neurons. The lab test done on rabbit recommended that it might be effectual up to three hours after a stroke in human beings. It is about the same time casement accessible for current clot-busting medication.
The drug CNB-001 seemed to have an effect on several grave mechanisms, which might keep brain cells animate after a stroke. The drug CNB-001 seemed to repair four signaling pathways which are known to help fuel the runaway obliteration of brain cells, explained lead researcher Dr Paul Lapchak from the Department of Neurology at Cedars-Sinai Medical Centre in Los Angeles.
Though strokes kill brain cells due to poor supply of oxygenated blood, this can stimulate chain reaction that can extend the damaged area and raised the levels of disability suffered by the patients. There is a great need for new treatments which can defend brain cells after a stroke and improve recovery, explained Sharlin Ahmed, research liaison officer at the Stroke Association.
She added this is the first significant research to show that it could be beneficial to stroke patients by encouraging new cells to grow and preventing cell death after a stroke. The results look promising, but it is still very early days and human trials need to be undertaken.